Physician profile
Danny Benjamin
NPI 1386699494
$6,298.77
in general payments reported to CMS, 2019-2025
42 companies · $616 in 2025
The $616 reported for 2025 was more than what 85% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $2,060 · 2021: $975 · 2022: $589 · 2023: $803 · 2024: $590 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $2,271.41 | 2020-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $470.90 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Aptima |
| Mayne Pharma Commercial LLC | $388.84 | 2021-2025 | |
| Fujirebio Diagnostics, Incorporated | $350.00 | 2019 | |
| Myovant Sciences INC. | $347.11 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $326.32 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $264.00 | 2019-2024 | |
| Astellas Pharma US INC | $253.22 | 2019-2024 | Veozah, Myrbetriq |
| Aspira Women'S Health INC | $222.21 | 2021 | |
| Medtronic, INC. | $159.65 | 2025 | Truclear |
| Daiichi Sankyo INC. | $124.08 | 2022-2025 | Injectafer |
| Therapeuticsmd, INC. | $119.70 | 2019-2022 | |
| Organon LLC | $107.75 | 2023-2025 | Nexplanon, Jada System |
| Coopersurgical, INC. | $86.09 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $83.04 | 2019-2025 | Slynd |
Show all 41 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Benjamin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.